vTv Therapeutics (NASDAQ:VTVT) reported positive topline results from its Phase 2 trial of TTP399 in Type 1 diabetes (T1D) patients.
TTP399 is designed to activate glucokinase enzyme, a key regulator of glucose metabolism, to increase glucose utilization and lower levels of glucose in the blood.
In the first part of the study, which enrolled 20 T1D patients using insulin pumps and continuous glucose monitoring (CGM), patients were treated with TTP399, or placebo, daily for 12 weeks.
Patients who received TTP399 showed a statistically significant mean reduction in HbA1c of 0.6%, compared with an HbA1c reduction of 0.1% in the placebo group. vTv also observed trends toward decreased insulin usage in the group treated with TTP399.
“While insulin remains the main line of treatment for T1D, we believe that adjunctive treatments such as TTP399 can lead to improvements in metabolic balance and favorable treatment outcomes for people living with T1D,” Esther Latres, Juvenile Diabetes Research Foundation director of research, said in a statement.
For the second part of the study, vTv is currently enrolling up to 90 T1D patients using either insulin pumps or multiple daily injection therapy, with optional CGM use. Topline results from this portion of the trial are expected in the first quarter of 2020.
